Latest Period
Q4 2025
Security Snapshot
Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) Institutional Ownership
CUSIP: 92539P101
13F Institutional Holders and Ownership History from Q2 2021 to Q4 2025
Institutions Reporting
1
Shares (Excl. Options)
24,000
Price
$14.33
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- VERV
- Shares outstanding
- 89,600,000
- Price per share
- $14.33
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 24,000
- Total reported value
- $344,000
- Share change
- -91,958
- Value change
- -$1,032,904
- Number of holders
- 1
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- VERV - Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 92539P101.
- 1 institution reported positions in Q4 2025.
- 4 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 6 to 1 between Q3 2025 and Q4 2025.
- Reported value moved from $1,373,904 to $344,000.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 1 institution filings for Q4 2025.
Investment Quick Answers
What is CUSIP 92539P101?
CUSIP 92539P101 identifies VERV - Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 92539P101:
Significant Owners of Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Pentwater Capital Management LP | 7.5% | $74,793,600 | 6,720,000 | Pentwater Capital Management LP | 30 Jun 2025 | |||
| BlackRock, Inc. | 7% | $33,730,520 | 6,177,751 | BlackRock, Inc. | 31 Mar 2025 | |||
| MILLENNIUM MANAGEMENT LLC | 4.9% | +6% | $23,626,659 | +$2,228,204 | 4,327,227 | +10% | Millennium Management LLC | 22 Apr 2025 |
| STATE STREET CORP | 3.8% | $17,667,179 | 3,235,747 | STATE STREET CORPORATION | 31 Dec 2024 |
As of 31 Dec 2025, 1 institutional investors reported holding 24,000 shares of Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV). This represents 0.03% of the company’s total 89,600,000 outstanding shares.
Institutional Holders of Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 24,000 | $344,000 | -$1,032,904 | $14.33 | 1 |
| 2025 Q3 | 115,958 | $1,373,904 | -$811,683,532 | $11.23 | 6 |
| 2025 Q2 | 72,945,086 | $819,295,389 | +$44,434,673 | $11.23 | 171 |
| 2025 Q1 | 80,771,198 | $369,085,158 | +$7,858,760 | $4.57 | 189 |
| 2024 Q4 | 78,639,409 | $443,556,247 | +$18,374,947 | $5.64 | 162 |
| 2024 Q3 | 75,254,197 | $364,246,240 | -$6,877,085 | $4.84 | 169 |
| 2024 Q2 | 76,097,271 | $371,356,824 | -$40,940,545 | $4.88 | 161 |
| 2024 Q1 | 81,620,346 | $1,084,037,472 | +$94,948,209 | $13.28 | 160 |
| 2023 Q4 | 74,728,462 | $1,041,701,866 | +$151,177,198 | $13.94 | 153 |
| 2023 Q3 | 63,876,196 | $847,014,395 | +$20,551,038 | $13.26 | 129 |
| 2023 Q2 | 61,868,280 | $1,159,985,777 | -$19,845,731 | $18.75 | 117 |
| 2023 Q1 | 63,279,802 | $911,809,584 | +$3,329,291 | $14.42 | 122 |
| 2022 Q4 | 62,650,868 | $1,212,293,655 | +$9,165,340 | $19.35 | 119 |
| 2022 Q3 | 60,715,323 | $2,083,329,620 | +$500,673,254 | $34.35 | 120 |
| 2022 Q2 | 45,570,006 | $695,801,719 | -$28,487,829 | $15.28 | 95 |
| 2022 Q1 | 46,647,422 | $1,064,194,664 | +$20,310,755 | $22.82 | 91 |
| 2021 Q4 | 45,147,057 | $1,662,481,200 | +$125,426,175 | $36.87 | 89 |
| 2021 Q3 | 38,717,676 | $1,813,712,011 | +$21,671,136 | $47.00 | 72 |
| 2021 Q2 | 37,677,821 | $2,254,528,000 | +$2,254,527,999 | $60.25 | 69 |